AG-1024

Catalog No.S1234 Batch:S123401

Print

Technical Data

Formula

C14H13BrN2O
Molecular Weight 305.17 CAS No. 65678-07-1
Solubility (25°C)* In vitro DMSO 61 mg/mL (199.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 3.000mg/ml (9.83mM) Taking the 1 mL working solution as an example, add 50 μL 60 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
Targets
IGF-1R [1]
(NIH-3T3 fibroblasts )		 Insulin Receptor [1]
(NIH-3T3 fibroblasts )
7 μM 57 μM
In vitro AG-1024 blocks the IGF-1 receptor and IR autophosphorylation with IC50 of 7 μM and 57 μM, respectively. AG-1024 also inhibits the receptor tyrosine kinase activity towards exogenous substrates (TKA) with IC50 values of 18 μM and 80 μM, respectively. [1] AG-1024 (10 μM) inhibits cell proliferation in a time-dependent manner, and induces apoptosis in MCF-7 cells at 48 hours by 20.1% and >40% when combined with irradiation (10 Gy), more potently than that of irradiation (10 Gy) alone by 11.8%, which is associated with a down-regulation of phospho-Akt1 and bcl-2, and up-regulation of Bax, p53 and p21. [2] AG-1024 significantly inhibits melanoma cell proliferation with an IC50 of <50 nM in the absence of serum, by blocking MAPK/ERK2 signaling, subsequently rapidly inducing pRb dephosphorylation and activation, and eventually the formation of growth suppressive pRb-E2F complexes. [3] AG-1024 treatment down-regulates the expression of Bcr-Abl and P-Akt, and up-regulates DNA-PKcs expression in UT7-9 and Ba/F3-p210 cells, leading to decreased clonogenic survival and proliferation. AG-1024 also significantly inhibits the proliferation of cells resistant to the BCR-ABL inhibitor STI571, which correlates with a dose-dependent decrease in Bcr-Abl protein expression. [4]
In vivo Administration of AG-1024 at a dose of 30 μg for 10 days significantly inhibits the tumor growth of Ba/F3-p210 xenograft in mice. [4]

Protocol (from reference)

Kinase Assay:[1]
  • Inhibition of IGF-1- and insulin-stimulated cellular proliferation

    NIH-3T3 cells overexpressing IGF-1 or insulin receptors are plated on 96-well plates (2,000-5,000 cells/well) and maintained overnight in complete medium. Cells are then changed to DMEM containing 1% FBS in the presence of 10 nM IGF-1 or insulin and various concentrations of AG-1024 for 120 hours. Medium is replaced every 48 hours. At the indicated periods of time, the medium is aspirated from the wells and 100 μL MTT is added to each well. The cells are then incubated for 4 hours at 37 °C and lysed by addition of 100 μL isoamylic alcohol and shaking for 20 minutes. The plate is then read in the ELISA reader at 570 and 690 nm. The IC50 value is calculated at the 120-hour time point.
Cell Assay:[2]
  • Cell lines

    MCF-7

  • Concentrations

    Dissolved in DMSO, final concentration 10 μM

  • Incubation Time

    24, 48 or 72 hours

  • Method

    Cells are exposed to AG-1024 for 24, 48 or 72 hours. For the determination of proliferation, cells are harvested and counted with trypan blue dye exclusion. Apoptosis is evaluated by dual staining of MCF-7 with fluoresceine anti-digoxigenin and propidium iodide. Briefly, fixed cells are washed with PBS, suspended in TdT buffer with TdT enzyme and Dig-dUTP for 60 minutes, and suspended in FITC blocking solution with anti-Dig-Fluorescein for 30 minutes at room temperature and kept in a dark place. Cells are then rinsed in buffer and resuspended in propidium iodide/RNase A solution for 30 minutes then analyzed by flow cytometry. For the assessment of phospho-Akt1, Bax, p53, bcl-2 and p21, cells are lysed and analyzed by western blot.
Animal Study:[4]
  • Animal Models

    Female nude mice implanted subcutaneously with Ba/F3-p210 cells

  • Dosages

    30 μg/day

  • Administration

    Injected i.p

References

  • https://pubmed.ncbi.nlm.nih.gov/9075698/
  • https://pubmed.ncbi.nlm.nih.gov/11747348/
  • https://pubmed.ncbi.nlm.nih.gov/12649208/
  • https://pubmed.ncbi.nlm.nih.gov/15494718/

Customer Product Validation

<p> </p><p>(A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.</p>

Data from [ Blood , 2013 , 122(9), 1621-33 ]

<p>FIG. 7. Gossypol sensitizes cancer cells to growth factor signaling pathway inhibitors. A, Forty-eight-hour treatments with the MEK inhibitor AZD6244 significantly reduced lung cancer A549 cell viability in a dose-dependent manner (0.1, 2, 5, and 10 μM) when combined with1 or 2 μM gossypol. B, Seventy-two-hour treatments with the EGFR inhibitor AG1478 (0.25, 0.5, and 1 μM) combined with 0.25 μM gossypol reduced cell viability in SKBR3 breast cancer cells. C, A 48-h treatment with the IGF-IR inhibitor AG1024 (0.25 and 0.5 μM) combined with 1 μM gossypol reduced cell viability in MCF-7 breast cancer cells. Serum-starved cells were incubated with vehicle (DMSO) as a control or with gossypol combined with inhibitors at indicated doses for 48-72 h. Cell viability with the different treatments was determined by MTS assays. Collected data were normalized to the DMSO treatment control, which was set to 100%. Each data point represented the average of values obtained from three wells of cells for each treatment. Differences between the untreated control and the inhibitor-treated samples were analyzed for the significance of difference using a Student’s t test, with P values indicated.</p>

Data from [ Mol Endocrinol , 2011 , 25, 2041-53 ]

(a-d) Effect of AG 1024 on 5HT3R-dependent neurogenic effects in the hippocampal dentate gyrus. (b) Representative images of the dentate gyrus double-stained for BrdU and DCX. Data for wild-type (WT) mice with respective drug treatments are shown. Scale bars, 100 μm.

Data from [ , , Mol Psychiatry, 2018, 23(4):833-842 ]

Selleck's AG-1024 Has Been Cited by 27 Publications

A Transcriptomics Analysis of the Regulation of Lens Fiber Cell Differentiation in the Absence of FGFRs and PTEN [ Cells, 2024, 13(14)1222] PubMed: 39056803
LTK and ALK promote neuronal polarity and cortical migration by inhibiting IGF1R activity [ EMBO Rep, 2023, 24(7):e56937] PubMed: 37291945
Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice [ Nat Biotechnol, 2022, 10.1038/s41587-022-01386-z] PubMed: 35879364
Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch [ Pharmaceuticals (Basel), 2022, 15(2)241] PubMed: 35215353
Targeting oncogenic mutations in colorectal cancer using cryptotanshinone [ PLoS One, 2021, 16(2):e0247190] PubMed: 33596259
Regulation of Hippo-YAP Signaling by Insulin-Like Growth factor-1 Receptor in the Tumorigenesis of Diffuse Large B-cell Lymphoma [ J Hematol Oncol, 2020, 13(1):77] PubMed: 32546241
Myeloid cells provide critical support for T-ALL in vivo [ The University of Texas at Austin, 2020, ] PubMed: None
An Autocrine IL-6/IGF-1R Loop Mediates EMT and Promotes Tumor Growth in Non-small Cell Lung Cancer. [ Int J Biol Sci, 2019, 15(9):1882-1891] PubMed: 31523190
mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma. [ Oncogene, 2019, 38(24):4669-4684] PubMed: 30745576
A novel 5HT3 receptor–IGF1 mechanism distinct from SSRI-induced antidepressant effects [Kondo M, et al. Mol Psychiatry, 2018, 23(4):833-842] PubMed: 28439104

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.